Doximity downgraded to Sell from Neutral at Goldman Sachs

Goldman Sachs analyst David Roman downgraded Doximity (DOCS) to Sell from Neutral with a price target of $64, up from $57, which implies 13% downside potential. The company’s growth profile does not support the stock’s current valuation, the analyst tells investors in a research note. The firm says Doximity’s slowing growth and “elevated” valuation create an unfavorable risk/reward profile.